Recce Pharmaceuticals – executive interview

In this interview, CEO James Graham discusses Recce Pharmaceuticals’ recent commencement of a registrational Phase III study in Indonesia for its topical gel formulation of lead compound RECCE 327 (R327G) in the treatment of diabetic foot infections (DFIs). He also describes the commercial opportunity for treating DFIs and other bacterial skin infections in Indonesian and other Association of Southeast Asian Nation countries, where R327G commercialisation could start in 2026 upon positive data from this Phase III study. Mr Graham also discusses the most recent positive human clinical trial data for R327G in the treatment of skin infections, and Recce Pharmaceuticals’ upcoming plans to start a separate Australian Phase III study of R327G for the treatment of acute bacterial skin and skin structure infections, a broader indication than DFIs. He also elaborates on the company’s strategy for advancing R327 to US clinical development, including recent successes through its collaborations with the US Department of Defense.

Recce Pharmaceuticals is an innovative, clinical-stage Australian company developing novel, broad-spectrum synthetic polymer anti-infective drugs to treat several infectious diseases, including DFIs and other bacterial skin and skin structure infections, as well as sepsis and complex urinary tract infections.